Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766958 · ClinicalTrials.gov registry record
A Registry to Evaluate the Performance of the BDX-XL2 Test
A clinical trial, sponsored by Biodesix.
- Completed
- Registry status
- 842
- Enrollment target
NCT03766958 is a clinical trial that has completed, run by Biodesix. The registered enrollment target is 842 participants.
The verdict
NCT03766958 has completed, sponsored by Biodesix.
- COMPLETED
- Registry status
- 842 participants
- Enrollment target
Study Summary
The purpose of the ORACLE Registry is to demonstrate clinical utility of the BDX-XL2 test; specifically, the potential to reduce unnecessary invasive procedures, such as biopsies and surgeries, on benign lung nodules while not significantly increasing the number of malignant lung nodules routed to CT surveillance. Clinical data will be collected from participating patients to evaluate the impact of the BDX-XL2 test when used in the clinical management of recently identified lung nodules assessed to have a low to moderate risk of cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 842 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2024-05-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03766958
The ClinicalTrials.gov registry entry for NCT03766958 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 842 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biodesix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03766958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03766958 about?
NCT03766958 is a clinical study titled "A Registry to Evaluate the Performance of the BDX-XL2 Test". The purpose of the ORACLE Registry is to demonstrate clinical utility of the BDX-XL2 test; specifically, the potential to reduce unnecessary invasive procedures, such as biopsies and surgeries, on benign lung nodules while not significantly increasing the number of malignant lung nodules routed to C...
What is the current status of trial NCT03766958?
This trial is currently completed. The enrollment target is 842 participants. The study started on 2018-10-16. Estimated completion is 2024-05-23.
Who is sponsoring clinical trial NCT03766958?
This trial is sponsored by Biodesix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.